

REMARKS

Claims 13-14, and 16-17 are pending in the application.

1. 35 U.S.C. §112, first and second paragraph Rejections

The Examiner rejected claims 13-14, and 16-17 under 35 U.S.C. §112, first and second paragraphs. Applicants have amended claims 13 and 17 as follows. Claim 13 has been amended to be directed only to a method of detecting colon cancer cells as well as deleting polypeptide fragment language. Claim 13 has also been amended to spell out the acronym EGLF6. Claim 17 has been amended to be directed only to a method of detecting colon cancer cells in biological samples consisting of tissues and cells. In light of these amendments, Applicants submit that the claims meet the standards of written description and enablement. Therefore, Applicants respectfully request that the 35 U.S.C. §112, first and second paragraph rejections be withdrawn.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance, and a Notice of Allowance is respectfully requested as soon as possible. If there are any questions regarding these amendments and remarks, or if further discussion would expedite allowance of the claims, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: April 29, 2004

By: Renée S. Polizotto
Renée S. Polizotto, Ph.D.
Agent for Applicants
Registration No.: 53,474
Customer No. 34285
NUVELO, INC.
675 Almanor Avenue
Sunnyvale, CA 94085
Tel: (408) 215-4522
Fax: (408) 524-8145